The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.
The Chicago-based imaging systems manufacturer said it plans to pay the purchase price in cash, believing the acquisition demonstrates its “continued commitment to cloud-enabled and AI-powered solutions.”
Boston Scientific stopped selling its Acurate TAVR systems after they underperformed in a few key trials and failed to gain FDA approval. Was it the right call?
According to Hexoskin, the newly cleared technology offers significant value for hospitals and health systems as well as researchers conducting clinical trials.
Filed in a Texas federal court, the complaint names Prime Imaging Partners and Memorial MRI & Diagnostic among numerous defendants, with the alleged auto-injury scheme occurring from 2019-2023.
The private equity-backed, Tennessee-based imaging group is expanding in Georgia and Missouri through partnerships with Piedmont and BJC HealthCare, respectively.
ACR, SIR and others altogether representing over 100,000 physicians recently wrote to 5 of the 7 Medicare Administrative Contractors to voice their concerns.
The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.
The Chicago-based imaging systems manufacturer said it plans to pay the purchase price in cash, believing the acquisition demonstrates its “continued commitment to cloud-enabled and AI-powered solutions.”
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/stack_views/public/2024-09/istock-1209664264.jpg.webp?itok=MzQCOefT)
